Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07209241) titled 'Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM' on Sept. 30.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of Pennsylvania
Condition:
Recurrent Glioblastoma
Intervention:
Biological: CART-EGFR-IL13Ra2 T cells
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: November 1, 2025
Target Sample Size: 12
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07209241
Publish...